Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis. The results also confirmed the technical reliability of the test, which successfully classified 97% of uveal melanomas submitted for testing in this case se


Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma

ADDIS ABABA, ETHIOPIA–(BUSINESS WIRE)–The International Trachoma Initiative (ITI), Pfizer Inc. and International Coalition for Trachoma Control (ICTC) partners announce Pfizer’s donation of the 500 millionth dose of Zithromax® (azithromycin) Tablets, an antibiotic used to treat trachoma in certain countries. The milestone marks significant achievement in global efforts to help eliminate this infectious and preventable eye disease that can lead to permanent blindness as a public health threat